New drug cocktail aims to beat tough myeloma
NCT ID NCT07334535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a four-drug regimen (isatuximab plus standard VRD) against the standard three-drug VRD in 117 newly diagnosed multiple myeloma patients who are not eligible for transplant and have high-risk features. The goal is to see if adding isatuximab leads to more patients achieving undetectable cancer levels (MRD negativity) at 12 months. Participants will receive treatment for up to 12 cycles followed by maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Isatuximab (a targeted antibody) combined with bortezomib, lenalidomide, and dexamethasone (standard chemotherapy drugs)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for high-risk multiple myeloma, potentially leading to deeper remissions and longer survival.
- What could go wrong
- This is a relatively small phase 4 trial (117 participants) and has not yet started recruiting. The added drug may increase side effects without guaranteeing better outcomes, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Junling Zhuang
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact